

## Barriers to implementation of stratified care in Primary Biliary Cholangitis

Corrigan, M; Hirschfield, Gideon M; Greenfield, Sheila; Parry, Jayne

DOI:

[10.1136/bmjgast-2018-000226](https://doi.org/10.1136/bmjgast-2018-000226)

License:

Creative Commons: Attribution-NonCommercial (CC BY-NC)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Corrigan, M, Hirschfield, GM, Greenfield, S & Parry, J 2019, 'Barriers to implementation of stratified care in Primary Biliary Cholangitis: a scoping exercise', *BMC Gastroenterology*, vol. 6, no. 1, e000226.  
<https://doi.org/10.1136/bmjgast-2018-000226>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise

Margaret Corrigan,<sup>1,2</sup> Gideon Hirschfield,<sup>1,2</sup> Sheila Greenfield,<sup>3</sup> Jayne Parry<sup>3</sup>

**To cite:** Corrigan M, Hirschfield G, Greenfield S, *et al.* Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise. *BMJ Open Gastro* 2019;**6**:e000226. doi:10.1136/bmjgast-2018-000226

Received 17 July 2018

Revised 31 August 2018

Accepted 7 September 2018

## ABSTRACT

Patients with primary biliary cholangitis (PBC) can be stratified into low-risk and high-risk groups based on their response to treatment. Newly published guidelines from the British Society of Gastroenterology suggest low-risk patients can be managed substantially in primary care. This represents a shift from existing practice and makes assumptions about service capacity and the willingness of both patients and health care practitioners (HCPs) to make this change. The aim of this paper is to identify possible barriers to the implementation of these new care pathways through review of the PBC-specific literature and by identifying the experiences of patients and HCPs managing a different condition with comparable patients and disease characteristics. Searches of MEDLINE, CINAHL and EMBASE were undertaken. Within the existing PBC literature there is little data surrounding stakeholder perspectives on place of care. Review of the breast cancer literature highlights a number of barriers to change including primary care practitioner knowledge and work load, communication between healthcare settings, and the significance of the established doctor–patient relationship. Further research is needed to establish the extent to which these barriers may surface when changing PBC care pathways, and the actions required to overcome them.

## INTRODUCTION

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic autoimmune liver disease. The incidence of PBC in the UK is 32.2 per 100 000,<sup>1</sup> with approximately 20 000 people presently affected. Incidence is higher in females compared with males (10:1) and in the fifth and sixth decade of life such that a woman over 40 years of age has a 1/1000 chance of having this condition.<sup>2</sup> While early natural history studies suggested that life expectancy from time of diagnosis was less than 10 years,<sup>3</sup> this is no longer true. Increasing understanding of the pathophysiology of the disease, along with the ability to diagnose PBC earlier in its course, and the widespread use of ursodeoxycholic acid (UDCA) has led to the recognition that, for many patients,

PBC is a chronic disease but not life limiting. The name changes from ‘primary biliary cirrhosis’ to ‘primary biliary cholangitis’ was adopted into use by clinicians, researchers and patients in 2015 to reflect the emerging evidence that only a minority of patients go on to develop cirrhosis and end-stage liver failure.

Patients with PBC can be categorised or ‘stratified’ into two groups (responders or non-responders) based on whether or not there is an improvement in biochemical parameters following 12 months of treatment with UDCA. Those who respond to treatment with UDCA (between 60% and 70% of all patients) do not go on to develop progressive disease and have a transplant free survival similar to the general population.<sup>4–7</sup>

Up until a few years ago, in the absence of second line treatment, those who failed to respond to UDCA were at risk of progression to end stage liver disease and liver transplantation, with younger patients and males with PBC over-represented in this group.<sup>8</sup> However, following recent positive outcomes in trials, obeticholic acid (OCA), a Farnesoid X receptor agonist has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of patients who have had an inadequate response to treatment with UDCA or were unable to tolerate UDCA.<sup>9</sup> However, despite the availability of effective treatment, there is no cure for the disease and even for those who respond, life-long treatment with UDCA is still required and patients will requirement regular follow-up.

Reflecting both the increased understanding of the natural history of PBC and the availability of second line therapy, recently published guidelines from the British Society of Gastroenterology<sup>10</sup> highlight the importance of formal risk stratification for all patients at 1-year postdiagnosis with management of treatment non-response or high-risk



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>University of Birmingham, NIHR Birmingham Biomedical Research Centre, Centre for Liver Research, Birmingham, UK

<sup>2</sup>Department of Liver medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>3</sup>University of Birmingham, Institute of Applied Health Research, Birmingham, UK

## Correspondence to

Dr Margaret Corrigan; m.corrigan@bham.ac.uk

patients necessitating discussion with specialist services for consideration of OCA or clinical trials. For those with low-risk disease, while long-term treatment and follow-up are required, it has been suggested that this does not necessarily need to take place in a hospital-based setting and there is the opportunity for an increased role for primary care services in the long-term care of these patients. These recommendations are echoed in the recent guidelines from the European Association for the Study of Liver Disease.<sup>11</sup>

New models of care for management of chronic liver disease as a whole are essential and timely. In contrast to other countries in Western Europe, rates of liver disease are increasing in the UK; over 600 000 people are known to have liver disease with 10% of these having cirrhosis and liver disease mortality has increased by 400% over the last 40 years.<sup>12</sup> The Lancet Commission on Liver Disease has highlighted the numerous challenges currently faced by the National Health Service (NHS) and by patients including inequalities in service provision (the so-called 'postcode lottery'). The Commission's recommendations included the need to improve access to specialist care and services for those most in need as well as increasing involvement from primary care and community services.<sup>12</sup>

However, changing patterns of established care requires 'buy in' from all users of the pathways: patients, stakeholders, and health care practitioners (HCPs) in primary, secondary and tertiary settings. This requires an appreciation of the various user's perspectives of current care, of the possible impacts any changes will have on them as new pathways are introduced, and in turn the identification of potential barriers to change and the facilitators required for these to be overcome. This paper seeks to identify what is already known about these factors in the currently available PBC literature. In addition, we also review the existing literature around patient and

HCP perspectives on follow-up in a comparable condition where recent changes in management parallel the proposed evolution of PBC in order to gain insights that may be relevant to reforms in PBC care.


## METHODS

### Review of the PBC literature

A scoping review was chosen with the goal of establishing the type and breadth of literature available.<sup>13</sup> The potential remained to perform a systematic review if the scoping study revealed a large body of relevant literature. Using the framework set out by Arksey and O'Malley,<sup>14</sup> the following stages were undertaken: (1) identification of the research question, (2) identification of relevant studies, (3) selection of studies, (4) charting of the data (5) collation, summarising and reporting of results.

The research question was divided into two parts. (1) What is the breadth and type of literature available looking at the perspectives of patients and clinicians on all aspects of PBC and its management? (2) Is there existing data looking specifically at how patients and clinicians view the role of primary care in the management of PBC?

A search of three electronic databases: MEDLINE, CINAHL and EMBASE was carried out. A schematic of the study selection process is shown in figure 1. The following search terms were used: Primary biliary cirrhosis OR primary biliary cholangitis AND quality OR experience OR perception\* OR perspective\* OR attitude\* OR expectation\* OR understand\* OR view\*. Eleven hundred and fifty-one distinct citations were identified by the initial database searches with 24 included in the final analysis. In order to establish whether there were any additional resources available but not captured by the initial electronic database searches, a review of all



**Figure 1** Study selection process for primary biliary cholangitis.

the reference lists from the 24 texts was undertaken; this yielded one further article. A search of the grey literature using Open Grey (<http://www.opengrey.eu>) using the search terms 'primary biliary cirrhosis' and 'primary biliary cholangitis' returned 18 and five citations, respectively. None were relevant to the research question. The key characteristics and emerging research themes of the 25 studies are summarised in [table 1](#).

### Choosing a comparable condition

A number of factors were deemed to be of relevance when selecting a comparable condition including the demographics of the patient population, availability of clear stratification parameters and the need for ongoing but minimal input long-term follow-up for low-risk groups. Possible conditions considered included other forms of liver disease, other chronic diseases (including autoimmune and non-autoimmune) and malignancies. Breast cancer satisfied the criteria (see [table 2](#)); it is mainly a disease of older females, patients are stratified after primary treatment into those who have achieved remission and those who have not responded, and even where remission has been achieved, there continues to be a need for a form of life-long input for responders that does not necessarily require specialist input.<sup>15</sup> A number of other parallels are also evident, including the ongoing psychological morbidity, and symptoms that may persist despite remission being achieved. In addition, issues around how best to follow-up patients who have undergone curative treatment remain a source of debate.<sup>16</sup> NICE guidelines on breast cancer from 2002 stated that all patients should be followed up for a minimum of 3 years (although they did not state how frequently patients should be seen) before care could be transferred back to primary care.<sup>17</sup> A systematic review of the breast cancer literature in 2007<sup>18</sup> identified seven randomised controlled trials which compared different forms of follow-up care both in terms of frequency of review and appropriate health-care professional. Overall, they found no difference in recurrence rates, survival or quality of life. The updated NICE guidelines in 2009<sup>19</sup> reflect the existing research and recommend patients decide how they would like to be followed up after primary treatment is completed with options including primary care, secondary care or shared care.

### Review of the breast cancer literature

The second scoping exercise again followed the Arksey and O'Malley structure.<sup>14</sup> As the topic of long-term follow-up in breast cancer survivorship has been widely studied, the goal of this review was to (1) gain an overview of the commonly occurring themes in this literature and (2) identify barriers to follow-up in primary care which may have potential relevance in PBC. An electronic database search was undertaken using the same three databases. A schematic of the sample selection process is shown in [figure 2](#). The following search terms were used: breast cancer OR breast carcinoma OR breast neoplasm

AND perspective\* OR opinion\* OR view\* OR attitude\* OR experience\* or perception\* AND discharge OR 'follow-up' OR 'primary care' OR 'secondary care' OR hospital\* OR special\* OR general practice\*. A date limit was set to cover 1996–2016 in order to capture data relevant to recent changes in breast cancer follow-up strategies between the 2002 and 2009 NICE guidelines and studies undertaken following this change in practice. Review of the reference lists from relevant articles did not identify any further relevant citations within the specified date range. For each study the following data were extracted: authorship, publication date, location, population type, sample size and barriers to primary care follow-up.

## RESULTS

### PBC literature

Twenty-five studies identified from the PBC literature were included in the final analysis ([table 1](#)). Seventeen quantitative studies were identified,<sup>20–36</sup> four qualitative,<sup>37–40</sup> two mixed methods study,<sup>41 42</sup> one literature review<sup>43</sup> and one patient narrative.<sup>44</sup> Of these studies, 24 focused on the patient perspective only, with one looking at both patient and physician perspectives.<sup>31</sup> The majority of the studies focused on symptoms and quality of life. Of those that took a qualitative or mixed approach, one study looked specifically at the impact of fatigue,<sup>37</sup> one at the experience of receiving a diagnosis<sup>40</sup> and the other at stigma associated with PBC.<sup>42</sup> Two studies explored the experience of living with PBC.<sup>39 41</sup>

While no studies directly addressed issues surrounding follow-up care and the role of primary, secondary and tertiary care, there were a number of emerging themes that are likely to be of relevance when looking at the impact of changes in the structure of care. Montali *et al*<sup>39</sup> identified the theme of 'delegitimation' and how, when patients look well (as is often the case in PBC), the impact of their disease is minimised by familial and social contacts. Discharge from specialist care to the primary care setting may further impact these perceptions both for the patient and their social contacts. The significance of the disease may be perceived as lesser when care is transferred to practitioners who may be seen as being less 'specialist' or 'expert'.<sup>40 44</sup> In addition, the stigma experienced by patients may also be influenced by new changes in care structure. A study looking at posts on an internet forum for patients with PBC revealed that a number of posts were related to stigma<sup>38</sup> and when directly asked many patients reported that they felt a degree of stigma associated with their disease.<sup>42</sup> This stigma seemed to stem not specifically from the diagnosis of PBC itself but with the associations between liver disease and cirrhosis with drugs and alcohol. Of note, this stigma was not just related to the perception of lay people but also to non-specialist HCPs.

### Breast cancer literature

From the breast cancer literature, 14 papers were included in the final analysis ([table 3](#)). Quantitative



**Table 1** Summary of research themes in PBC addressing patient and physician perspectives on disease

Authorship	Publication date	Location	Methodology	Population (size of sample with PBC)	Research question
Blackburn <i>et al</i> <sup>20</sup>	2007	UK	Quantitative	Patients (n=24)	Are patients with fatigue more psychologically impaired than those without fatigue and is there a role for CBT?
Dyson <i>et al</i> <sup>21</sup>	2016	UK	Quantitative	Patients (n=2055)	Impact of age at presentation on quality of life and the role of symptomatology
Fahey <sup>43</sup>	1999	UK	Literature review	Patients	Experience of women living with PBC and how understanding this may improve nursing care
Gross <i>et al</i> <sup>22</sup>	1999	USA	Quantitative	Patients post liver transplant (n=157, 42% PBC)	Quality of life post-transplant Comparison between PBC and PSC patients Relationship between quality of life and clinical factors
Hale <i>et al</i> <sup>44</sup>	2012	UK	Patient narrative	Patients (n=1)	Experience of living with fatigue
Huet <i>et al</i> <sup>23</sup>	2000	Canada	Quantitative	Patients (n=116) Healthy controls	Validation of the fatigue impact score in a large patient cohort Link between fatigue and mental health status Relationship between psychosocial and physical factors
Ismond <i>et al</i> *conference abstract only <sup>41</sup>	2018	Canada	Mixed methods (quantitative with post hoc qualitative analysis)	Patients (n=119)	Experience of living with PBC Impact on daily life and relationships
Jorgensen <sup>37</sup>	2006	USA	Qualitative	Patients (n=8)	Experience of living with fatigue
Lasker <i>et al</i> <sup>38</sup>	2005	USA	Qualitative	Patients (n=275)	Why do patients use internet resources? Does disease stage affect disease experience? What are the similarities between issues experiences by patients with PBC and those with other chronic disease?
Lasker <i>et al</i> <sup>24</sup>	2010	USA	Quantitative	Patients on waiting list or post-transplant (n=100)	Uncertainty and how it relates to quality of life scores
Mells <i>et al</i> <sup>25</sup>	2013	UK	Quantitative	Patients (n=2402)	Quality of life scores and the role of fatigue, depression, sleep, social and cognitive function
Miura <i>et al</i> *conference abstract only <sup>26</sup>	2016	Japan	Quantitative	Patients (n=217)	Symptom profile and impact on quality of life
Montali <i>et al</i> <sup>39</sup>	2011	Italy	Qualitative	Patients (n=23)	Illness experience of women with PBC, sick role and relationship with others
Navasa <i>et al</i> <sup>27</sup>	1996	Spain	Quantitative	Patients post liver transplant (n=29)	Quality of life scores, complications and use of medical services post-transplant
Pearce <i>et al</i> <sup>40</sup>	2011	UK	Qualitative	Patients (n=28+)	Experience of receiving a diagnosis of PBC Use of this information to develop resources for patients at diagnosis
Poupon <i>et al</i> <sup>28</sup>	2004	France	Quantitative	Patients (n=276)	Comparison of quality of life scores among patients compared with healthy controls Relationship between clinical parameters and quality of life Impact of UDCA use on quality of life
Raszeja-Wyszomirska <i>et al</i> <sup>29</sup>	2015	Poland	Quantitative	Patients (n=205) Healthy controls	Comparison of quality of life domains between patients and controls Impact of patient and disease related factors on quality of life
Rishe <i>et al</i> <sup>30</sup>	2008	USA	Quantitative	Patients (n=238)	Experience of living with itch
Saich <i>et al</i> *conference abstract only <sup>31</sup>	2015	USA	Quantitative	Patients (n=214) and physicians (n=322)	Comparison of patient perceptions of care versus physician perspectives

Continued

**Table 1** Continued

Authorship	Publication date	Location	Methodology	Population (size of sample with PBC)	Research question
Selmi <i>et al</i> <sup>32</sup>	2007	USA	Quantitative	Patients (n=1032)	Comparison of activity scores, symptoms and social life scores between patients and healthy controls
Sogolow <i>et al</i> <sup>42</sup>	2010	USA	Mixed methods	Patients (n=100)	Experience of stigma associated with diagnosis Why do some women experience more stigma than others? What impact does stigma have on quality of life?
Stanca <i>et al</i> <sup>33</sup>	2005	USA	Quantitative	Patients (n=70)	Impact of fatigue on quality of life
Untas <i>et al</i> <sup>34</sup>	2015	France	Quantitative	Patients (n=130)	Quality of life perception among women with PBC compared with a group of women with diabetes
Yagi <i>et al</i> *conference abstract only <sup>35</sup>	2016	Japan	Quantitative	Patients (n=180)	Comparison between patient and physician reported symptoms
Wong <i>et al</i> <sup>36</sup>	2008	China	Quantitative	Patients (n=44)	Comparison of symptoms scores, quality of life scores and depression scores between patients with PBC and two control groups (hypertension and chronic hepatitis B)

CBT, cognitive behavioural therapy; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid.

methods were used in eight of the studies,<sup>45–52</sup> five used qualitative methods<sup>53–58</sup> and one mixed methods study<sup>58</sup> was identified. Nine studies looked at the views of the patient population,<sup>46–48 50 53–57</sup> six included primary care clinicians<sup>46 48 49 55 57 58</sup> and five included specialists (comprising surgeons, oncologists and nurses).<sup>45 51 52 55 56</sup>

Barriers to primary care follow-up identified included lack of knowledge among primary care physicians which was a recurrent theme among patients,<sup>50 53 54 57</sup> specialists<sup>45 51 56</sup> and primary care physicians themselves.<sup>49 57 58</sup> Allied to this concern was a fear that recurrence could be missed which was expressed by both primary care and specialist care<sup>55</sup> with some primary care clinicians expressly mentioning medicolegal concerns.<sup>46 55</sup> There was an association between cases where patients had experienced delays at the time of initial diagnosis and reduced confidence in their primary care practitioners ability to provide adequate follow-up.<sup>57</sup> When asked to rate their survival outcomes in different healthcare settings, patients felt that their chance of survival long term was higher if they were followed up by a specialist.<sup>47</sup>

In terms of practical aspects of care, both patients and doctors felt that primary care clinicians are already over-worked,<sup>46 49 53</sup> that communication between primary care and specialists was poor<sup>54 55</sup> and this may impact on care.

Specialists highlighted that they would lose long-term outcome data if they did not follow-up patients themselves.<sup>45</sup> They also described the relationship that forms with patients over time which was echoed by patients who described forming a bond with their specialists and feelings of abandonment when discharged.<sup>54 55</sup> The specialists reported the positive reinforcement they received from following up patients in remission rather than just seeing patients with complications and more advanced/untreatable disease.<sup>55</sup>


## DISCUSSION

This scoping exercise identified the paucity of available literature exploring patient and HCP perspectives on the follow-up and management of PBC and a lack of any data around the role of primary care in the long-term management of patients with low-risk PBC. However, studies reporting stakeholder perspectives on changes to the delivery of breast cancer follow-up care have shown that not all patients or practitioners are comfortable with management being located substantially in the primary care setting. A series of themes emerged which have relevance to proposed care pathway changes including the knowledge base and workload of primary care,

**Table 2** Comparison of primary biliary cholangitis and breast cancer

	PBC	Breast cancer
Gender	F:M 9:1 (2)	F:M 99:1 (40)
Age	Most common in fifth and sixth decade <sup>2</sup>	50% over 65 <sup>15</sup>
Prognosis	70% response rate <sup>6</sup>	>70% 5-year survival <sup>15</sup>
Long-term treatment required	Yes, UDCA	Some cases—hormonal treatment
Long-term symptoms	Itch and fatigue	Lymphoedema

PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.



**Figure 2** Study selection process for breast cancer.

communication between care settings and the importance of the doctor–patient relationship. Within the data available specifically for PBC, the impact of delegitimisation and stigmatisation felt by PBC patients is likely to be of relevance when developing new strategies for follow-up care.

This scoping review has identified a gap in the literature around patient and HCP perspectives on management in primary care and the need for further study in this area to look specifically at the potential concerns of users of this pathway and whether or not the themes identified in this scoping review are relevant, if there are additional barriers or facilitators not identified here and, if so, how they can be overcome.

As is common with the use of a scoping review rather than a systematic review, there was a focus on identifying the breadth of literature available rather than looking at the available studies in depth and the quality of the studies identified was not assessed. However, the identification that there is little relevant literature in this field meant that this was less important. We aimed to conduct a comprehensive search of the literature, using a multiple database strategy. However, it is possible that some relevant articles were missed. The lack of identification of additional relevant studies from reference lists of the chosen papers would support the belief that the search identified the relevant data in the field. Finally, it is not possible to know whether, and to what extent, any of the conditions considered by the authors for the second stage of the scoping study (including other forms of autoimmune disease, other forms of chronic liver disease and breast cancer) truly act as comparators to PBC. While breast cancer was chosen as a comparator condition due to its similarities to PBC in terms of demographics of the patient population, this decision makes the assumption about the overall importance of patient demographics in determining its healthcare related behaviours. In

addition, there are likely to be fundamental differences in comparing a malignant and non-malignant condition that will impact on how patients and clinicians view their future care needs. Finally, PBC as a rare disease is likely to pose different challenges to breast cancer which is now relatively common.

## CONCLUSION

The recent guidelines from both the UK and European Societies propose a shift towards individualised care for patients with PBC. While individualised care is not explicitly defined, one potential consequence that is discussed in the British Guidelines is the discharge of patients deemed ‘low risk’ from hospital care to follow-up in primary care. The feasibility of this strategy is unclear and as such, the purpose of this scoping review was to identify the breadth and depth of the data already available about patient and clinician perspectives on management in primary care in order to identify facilitators and barriers to implementing this in practice. This review however highlighted that there is in fact a lack of data and that in order to be able to definitively answer the question of feasibility within PBC, further study may be required.

In developing a stratified approach to the care of the patient with PBC it will be essential to frame changes in care around high quality research. Underpinning this are opportunities to change practice by first of all an emphasis on education. This should address specific education for patients with PBC, and for primary care physicians, a broader education effort on the management of chronic liver diseases. With such an approach there would then be a greater opportunity to perhaps implement further change through targeted education, and use of smart technology/Apps to aid individualise risk assessment and changes to care pathways. Any approaches to change would require sensitive implementation adapted to local

**Table 3** Summary of themes identified in breast cancer literature

Authorship	Publication date	Location	Methodology	Population (size of sample)	Findings/themes identified
Adewuyi-Dalton <i>et al</i> <sup>53</sup>	1998	UK	Qualitative—face to face one on one interviews	Patients (n=109)	GPs—overworked; lack specialist knowledge; specialist care less important over time as concern about recurrence lessens
Brennan <i>et al</i> <sup>51</sup>	2010	Australia	Quantitative—questionnaire	Secondary care (n=217)	GPs need more training to follow-up patients
Brennan <i>et al</i> <sup>54</sup>	2011	Australia	Qualitative—telephone interviews	Patients (n=20)	Advantages GP care: convenience, reduced travel involved, take pressure off specialists Disadvantages of GP care: poor communication between specialist and GP, GPs lack of knowledge, established relationship with specialist during treatment
Dawes <i>et al</i> <sup>58</sup>	2015	USA	Mixed methods—questionnaire and focus group	Primary care (Survey n=59) Focus group n=36+	Favoured specialists to provide follow-up care Lack of knowledge especially endocrine treatment
Donnelly <i>et al</i> <sup>45</sup>	2007	UK	Quantitative—questionnaire	Secondary care (n=256)	Advantages of GP care: reduced clinic workload Disadvantages: lack of training, loss of outcome data
Kantsiper <i>et al</i> <sup>55</sup>	2009	USA	Qualitative—focus group	Patients (n=21) Primary care (n=15) Secondary care (n=160)	Specialists are experts and GPs role is in referral not management. Feelings of abandonment on discharge Fear of missing recurrence and medicolegal implications, not able to keep up to date with information, poor communication from specialists Better at detecting recurrence and managing side effects than GPs, like following up survivors (positive experience), establish bond with patient
Kerrigan <i>et al</i> <sup>46</sup>	2014	Ireland	Quantitative	Patients (n=87) Primary care (n=53)	Supportive of GP care: able to explain breast cancer, able to perform examination, easy links to specialist if needed Increased workload and costs, concern regarding medicolegal aspects of care
Kwast <i>et al</i> <sup>56</sup>	2013	Netherlands	Qualitative—face to face interviews	Patients (n=23) Clinicians (n=18)	GP—role in psychosocial aspects of care; lacks specialist knowledge; too busy GP care cheaper; lack specialist knowledge
Luker <i>et al</i> <sup>57</sup>	2000	UK	Qualitative—face to face/telephone interviews	Patients (n=67) Primary care (n=31)	GP—lacks knowledge; delay in diagnosis associated with decreased confidence in follow-up Difficult to keep up to date with new information, prognostication challenging
Mao <i>et al</i> <sup>50</sup>	2009	USA	Quantitative	Patients (n=300)	Holistic care through GP; psychosocial aspects of management; variable breast cancer specific knowledge
Mayer <i>et al</i> <sup>47</sup>	2012	Canada	Quantitative	Patients (n=218)	Specialist visit reduces anxiety and improves survival compared with primary care
Roorda <i>et al</i> <sup>49</sup>	2013	Netherlands	Quantitative—questionnaires	Primary care (n=502)	40% of GPs happy to provide exclusive care after 5 years; barriers—patient preference, lack of knowledge, workload improving GP care improving GP care—active discharge from specialist care, written information, education, easy access back to specialist care if required
Smith <i>et al</i> <sup>48</sup>	2015	Canada	Quantitative	Patients (n=1065) Primary care (n=587)	Confident in GPs ability to screen for recurrence, less confident in GPs managing osteoporosis, hormonal treatment Confident in screening for recurrence, lower confidence in lymphoedema, family counselling, psychosocial aspects
Van Hezewijk <i>et al</i> <sup>62</sup>	2011	Netherlands	Quantitative—questionnaire	Secondary care (n=130)	GPs should play a minor role in follow-up. Reasons not specified

GP, general practitioner.



resources: for example, where large group practices and primary networks exist in primary care, opportunities to use a few embedded primary care liver champions may be effective, whereas in rural areas, IT/nurse supported change to care for GPs may be better.

Across the various models of healthcare delivery, it will be essential to evaluate feasibility of stratified care for patients with PBC in many different settings and healthcare models. Solutions for urban areas may, for example, be distinct to those for rural environments, and obstacles to implementation may include economic and personnel issues. Nevertheless, there exists the opportunity to be innovative in-service design and then to evaluate the impact of any service change.

We believe the similarities between the patient, disease and management characteristics of postsurgery breast cancer and low-risk PBC patients to be such that it is reasonable to anticipate comparable barriers will emerge to the implementation of the new management guidelines for PBC. Dedicated research involving patients and clinicians is still required to confirm that barriers to change exist, to identify what these barriers are and to plan strategies for intervention in this group of patients and clinicians. This information will be relevant not only to the possible future implementation of stratified care models in the PBC population but will also be applicable to other rare chronic diseases including, but not exclusive to, liver disease.

**Acknowledgements** This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Contributors** MC contributed to the conception and design of this scoping review, the acquisition and analysis of the data, and drafted and revised the paper for final submission. GH, SG and JP contributed to conception and design and revised the draft paper for final submission. MC acts as the guarantor for this submission.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** MC and GH are collaborating investigators for UK-PBC, a MC stratified medicine platform. SG and JP declare no competing interests.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No additional data are available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

- James OF, Bhopal R, Howel D, *et al*. Primary biliary cirrhosis once rare, now common in the United Kingdom? *Hepatology* 1999;30:390–4.
- Mells GF, Hirschfield GM. *Genetics of primary biliary cirrhosis*. eLS, 2013.
- Prince M, Chetwynd A, Newman W, *et al*. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. *Gastroenterology* 2002;123:1044–51.
- Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. *Gastroenterology* 2006;130:715–20.
- Corpechot C, Abenavoli L, Rabahi N, *et al*. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. *Hepatology* 2008;48:871–7.
- Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. *J Hepatol* 2011;55:1361–7.
- Kuiper EMM, Hansen BE, de Vries RA, *et al*. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. *Gastroenterology* 2009;136:1281–7.
- Carbone M, Mells GF, Pells G, *et al*. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. *Gastroenterology* 2013;144:560–9.
- National Institute for Health and Care Excellence. *Obeticholic acid for treating primary biliary cholangitis*. nice.org.uk/guidance/ta443: NICE; 2017. Report no.: TA443 contract No.: TA443, 2017.
- Hirschfield GM, Dyson JK, Alexander GJM, *et al*. The British society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. *Gut* 2018;67:1568–94.
- European association for the study of the liver. Electronic address eee, European association for the study of the liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. *J Hepatol* 2017;67:145–72.
- Williams R, Aspinall R, Bellis M, *et al*. Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *The Lancet* 2014;384:1953–97.
- Armstrong R, Hall BJ, Doyle J, *et al*. 'Scoping the scope' of a cochrane review. *Journal of Public Health* 2011;33:147–50.
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology* 2005;8:19–32.
- Cancer Research UK. Breast Cancer statistics. Available: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer>
- Taggart F, Donnelly P, Dunn J. Options for early breast cancer follow-up in primary and secondary care - a systematic review. *BMC Cancer* 2012;12.
- National Institute for Clinical Excellence. *Improving outcomes in breast cancer*, 2002.
- Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. *Br J Cancer* 2007;96:1625–32.
- National Institute of Clinical Excellence. *Early and locally advanced breast cancer: diagnosis and treatment*, 2009.
- Blackburn P, Freeston M, Baker CR, *et al*. The role of psychological factors in the fatigue of primary biliary cirrhosis. *Liver International* 2007;27:654–61.
- Dyson JK, Wilkinson N, Jopson L, *et al*. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. *Aliment Pharmacol Ther* 2016;44:1039–50.
- Gross CR, Malinchoc M, Kim WR, *et al*. Quality of life before and after liver transplantation for cholestatic liver disease. *Hepatology* 1999;29:356–64.
- Huet P-M, Deslauriers J, Tran A, *et al*. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. *Am J Gastroenterology* 2000;95:760–7.
- Lasker JN, Sogolow ED, Olenik JM, *et al*. Uncertainty and liver transplantation: women with primary biliary cirrhosis before and after transplant. *Women & Health* 2010;50:359–75.
- Mells GF, Pells G, Newton JL, *et al*. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. *Hepatology* 2013;58:273–83.
- Miura K, Tanaka A, Takikawa H. Assessment of quality of life of Japanese patients with primary biliary cirrhosis using PBC-40. *Hepatology International* 2016;10:S37–S8.
- Navasa M, Forns X, Sánchez V, *et al*. Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. *Journal of Hepatology* 1996;25:129–34.
- Poupon RE, Chretien Y, Chazouillères O, *et al*. French pBC Study Group. Quality of life in patients with primary biliary cirrhosis. *Hepatology* 2004;40:489–94.
- Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, *et al*. Assessment of health related quality of life in Polish patients with primary biliary

- cirrhosis. *Clinics and Research in Hepatology and Gastroenterology* 2016;40:471–9.
30. Rishe E, Azarm A, Bergasa NV. Itch in Primary Biliary Cirrhosis: A Patients' Perspective. *Acta Derm Venereol* 2008;88:34–7.
  31. Saich A, Swanson H, Mayer TJ, Intercept Pharmaceuticals. Physician versus patient perceptions of medical care quality in primary biliary cirrhosis. In: *American Association for the study of liver disease*. San Francisco, CA: Hepatology, 2015.
  32. Selmi C, Gershwin ME, Lindor KD, et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. *Hepatology* 2007;46:1836–43.
  33. Stanca CM, Bach N, Krause C, et al. Evaluation of fatigue in U.S. Patients with primary biliary cirrhosis. *Am J Gastroenterol* 2005;100:1104–9.
  34. Untas A, Boujut E, Corpechot C, et al. Quality of life and illness perception in primary biliary cirrhosis: a controlled cross-sectional study. *Clinics and Research in Hepatology and Gastroenterology* 2015;39:52–8.
  35. Yagi M, Tanaka A, Miura K, et al. The assessment of subjective symptoms and patient-reported outcomes in patients with primary biliary cholangitis using PBC-40. *Journal of Gastroenterology and Hepatology* 2016;31.
  36. Wong GL-H, Law FM-Y, Wong VW-S, et al. Health-related quality of life in Chinese patients with primary biliary cirrhosis. *Journal of Gastroenterology and Hepatology* 2008;23:592–8.
  37. Jorgensen R. A phenomenological study of fatigue in patients with primary biliary cirrhosis. *Journal of Advanced Nursing* 2006;55:689–97.
  38. Lasker JN, Sogolow ED, Sharim RR. The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis Mailinglist. *J Med Internet Res* 2005;7:e10.
  39. Montali L, Frigerio A, Riva P, et al. 'It's as if PBC didn't exist': The illness experience of women affected by primary biliary cirrhosis. *Psychology & Health* 2011;26:1429–45.
  40. Pearce RM, Jones DE, Newton JL. Development of an evidence-based patient information medium: empowering newly diagnosed patients with primary biliary cirrhosis. *J Vis Commun Med* 2011;34:4–13.
  41. Ismond K, Azziz B, Wright G, et al. Self reported experiences of patients living with primary biliary cholangitis (pBC) and ursodiol. *Hepatol Int* 2018;12(supplement 2).
  42. Sogolow ED, Lasker JN, Sharim RR, et al. Stigma and liver disease. *Illness, Crisis & Loss* 2010;18:229–55.
  43. Fahey S. The experience of women with primary biliary cirrhosis: a literature review. *J Adv Nurs* 1999;30:506–12.
  44. Hale M, Newton JL, Jones DEJ. Fatigue in primary biliary cirrhosis. *BMJ* 2012;345:e7004.
  45. Donnelly P, Hiller L, Bathers S, et al. Questioning specialists' attitudes to breast cancer follow-up in primary care. *Ann Oncol* 2007;18:1467–76.
  46. Kerrigan D, Waters P, Ryan M, et al. Follow up arrangements for breast cancer patients: is it appropriate to transfer surveillance to general practitioners. *Irish Medical Journal* 2014;107:273–5.
  47. Mayer EL, Gropper AB, Neville BA, et al. Breast cancer survivors' perceptions of survivorship care options. *JCO* 2012;30:158–63.
  48. Smith SL, Murchison S, Singh-Carlson S, et al. Survivorship care in breast cancer: perceptions of patients and primary care physicians. *Canadian family physician* 2015;61:277–83.
  49. Roorda C, Berendsen AJ, Haverkamp M, et al. Discharge of breast cancer patients to primary care at the end of hospital follow-up: a cross-sectional survey. *European Journal of Cancer* 2013;49:1836–44.
  50. Mao JJ, Bowman MA, Stricker CT, et al. Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients. *JCO* 2009;27:933–8.
  51. Brennan ME, Butow P, Spillane AJ, et al. Survivorship care after breast cancer: follow-up practices of Australian health professionals and attitudes to a survivorship care plan. *Asia Pac J Clin Oncol* 2010;6:116–25.
  52. van Hezewijk M, Hille ETM, Scholten AN, et al. Professionals' opinion on follow-up in breast cancer patients; perceived purpose and influence of patients' risk factors. *European Journal of Surgical Oncology* 2011;37:217–24.
  53. Adewuyi-Dalton R, Ziebland S, Grunfeld E, et al. Patients' views of routine hospital follow-up: a qualitative study of women with breast cancer in remission. *Psycho-Oncology* 1998;7:436–9.
  54. Brennan ME, Butow P, Marven M, et al. Survivorship care after breast cancer treatment – Experiences and preferences of Australian women. *The Breast* 2011;20:271–7.
  55. Kantsiper M, McDonald EL, Geller G, et al. Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. *J Gen Intern Med* 2009;24:459–66.
  56. Kwast ABG, Drossaert CHC, Siesling S, et al. Breast cancer follow-up: from the perspective of health professionals and patients. *Eur J Cancer Care* 2013;22:754–64.
  57. Luker K, Beaver K, Austin L, et al. An evaluation of information cards as a means of improving communication between hospital and primary care for women with breast cancer. *J Adv Nurs* 2000;31:1174–82.
  58. Dawes AJ, Hemmelgarn M, Nguyen DK, et al. Are primary care providers prepared to care for survivors of breast cancer in the safety net? *Cancer* 2015;121:1249–56.